VEGFA and pachyonychia congenita: A series of phase III clinical trials (NCT00088894, NCT01214720, NCT00471146, NCT00541021) in patients with advanced or metastatic PC failed to enhance OS after treatment with VEGF inhibitors, including bevacizumab (humanized anti-VEGF-A monoclonal antibody), sorafenib (VEGF-R inhibitor), and axitinib (tyrosine kinase inhibitor, TKI), along with gemcitabine or gemcitabine/erlotinib [32,33,34,35,36].